Patterns of mutations in nine cancer-related genes and PAF development among smoking male patients diagnosed with bladder cancer.

Q3 Biochemistry, Genetics and Molecular Biology

Tumor Biology Pub Date : 2023-01-01 DOI:10.3233/TUB-220032

Eman Alshehri, Amal M Al-Dogmi, Tahani Mohamed Ibrahim Al-Hazani, Maha Abdulla Alwaili, Fatmah Ahmed Safhi, Lina Mohammed Alneghery, Areej Saud Jalal, Ibtesam Sanad Alanazi, Fatima Abdullah AlQassim, Mashael Alhumaidi Alotaibi, Wedad Saeed Al-Qahtani

{"title":"Patterns of mutations in nine cancer-related genes and PAF development among smoking male patients diagnosed with bladder cancer.","authors":"Eman Alshehri, Amal M Al-Dogmi, Tahani Mohamed Ibrahim Al-Hazani, Maha Abdulla Alwaili, Fatmah Ahmed Safhi, Lina Mohammed Alneghery, Areej Saud Jalal, Ibtesam Sanad Alanazi, Fatima Abdullah AlQassim, Mashael Alhumaidi Alotaibi, Wedad Saeed Al-Qahtani","doi":"10.3233/TUB-220032","DOIUrl":null,"url":null,"abstract":"Background: Smoking is one of the most popular risk factors provoking bladder cancer (BC). This research intended to estimate cigarette smoking effect involving PAF signs between smoking patients with BC and non-smoking patients with same diagnosis to define relations with pathological characteristics and their prognosis on zero-relapse and disease-associated recovery.Methods: Two groups of smokers (n = 54) and non-smokers (n = 62) were selected. Both cohorts of patients had BC. They were evaluated utilizing NGS on 9 cancer-related genes and confirmed through the Sanger DNA sequencing and histopathological tests based on H&E staining. The factor of smoking and impact of PAF development by ELISA assay and PAF-R manifestation in terms of immunochemical evaluation on BC areas comparing to a control group (n = 30) was examined involving healthy contributors, including the use of well-designed statistical trials.Results: The multivariate evaluation showed considerable rise in mutation patterns related to smoking among BC patients (group 3), increase in PAF development (***P<0.001) and vivid signs of PAF-R contrasted to non-smokers with BC (group 2) and control group (group 1). All the identified biological changes (gains/losses) were recorded at the same locations in both groups. Patients from group 3 held 3-4 various mutations, while patients from group 2 held 1-3 various mutations. Mutations were not identified in 30 respondents from control group. The most repeated mutations were identified in 3 of 9 examined genes, namely TP53, PIK3CA and PTEN, with highest rates of increase in Group 3. Moreover, histopathological tests revealed barely identifiable and abnormal traits in BC tissues, i.e. were without essential histopathological changes between groups 2 and 3.Conclusion: Smoking of cigarettes provokes PAF development due to urothelial inflammation and rise of mutations in 9 cancer-related genes. These are indicative factors of inducing BC.","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":"45 1","pages":"1-14"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumor Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/TUB-220032","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Smoking is one of the most popular risk factors provoking bladder cancer (BC). This research intended to estimate cigarette smoking effect involving PAF signs between smoking patients with BC and non-smoking patients with same diagnosis to define relations with pathological characteristics and their prognosis on zero-relapse and disease-associated recovery.

Methods: Two groups of smokers (n = 54) and non-smokers (n = 62) were selected. Both cohorts of patients had BC. They were evaluated utilizing NGS on 9 cancer-related genes and confirmed through the Sanger DNA sequencing and histopathological tests based on H&E staining. The factor of smoking and impact of PAF development by ELISA assay and PAF-R manifestation in terms of immunochemical evaluation on BC areas comparing to a control group (n = 30) was examined involving healthy contributors, including the use of well-designed statistical trials.

Results: The multivariate evaluation showed considerable rise in mutation patterns related to smoking among BC patients (group 3), increase in PAF development (***P<0.001) and vivid signs of PAF-R contrasted to non-smokers with BC (group 2) and control group (group 1). All the identified biological changes (gains/losses) were recorded at the same locations in both groups. Patients from group 3 held 3-4 various mutations, while patients from group 2 held 1-3 various mutations. Mutations were not identified in 30 respondents from control group. The most repeated mutations were identified in 3 of 9 examined genes, namely TP53, PIK3CA and PTEN, with highest rates of increase in Group 3. Moreover, histopathological tests revealed barely identifiable and abnormal traits in BC tissues, i.e. were without essential histopathological changes between groups 2 and 3.

Conclusion: Smoking of cigarettes provokes PAF development due to urothelial inflammation and rise of mutations in 9 cancer-related genes. These are indicative factors of inducing BC.

查看原文本刊更多论文

诊断为膀胱癌的吸烟男性患者中9种癌症相关基因的突变模式和PAF的发展

背景:吸烟是引起膀胱癌(BC)最常见的危险因素之一。本研究旨在评估吸烟合并BC患者与非吸烟患者在相同诊断的情况下吸烟对PAF体征的影响，以确定其病理特征及其零复发和疾病相关康复预后的关系。方法:选择吸烟者(n = 54)和非吸烟者(n = 62)两组。两组患者均患有BC。利用NGS对9个癌症相关基因进行评估，并通过Sanger DNA测序和基于H&E染色的组织病理学检查进行确认。通过ELISA检测吸烟因素和PAF发展的影响，以及与对照组(n = 30)相比，在BC区域的免疫化学评价中PAF- r的表现，包括使用精心设计的统计试验。结果:多因素评估显示，BC患者中吸烟相关的突变模式显著增加(第3组)，PAF发展增加(*** p)。结论:吸烟引起尿路上皮炎症和9种癌症相关基因突变增加，从而引发PAF发展。这些都是诱发BC的指示性因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tumor Biology 医学-肿瘤学

CiteScore

5.40

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： Tumor Biology is a peer reviewed, international journal providing an open access forum for experimental and clinical cancer research. Tumor Biology covers all aspects of tumor markers, molecular biomarkers, tumor targeting, and mechanisms of tumor development and progression. Specific topics of interest include, but are not limited to: Pathway analyses, Non-coding RNAs, Circulating tumor cells, Liquid biopsies, Exosomes, Epigenetics, Cancer stem cells, Tumor immunology and immunotherapy, Tumor microenvironment, Targeted therapies, Therapy resistance Cancer genetics, Cancer risk screening. Studies in other areas of basic, clinical and translational cancer research are also considered in order to promote connections and discoveries across different disciplines. The journal publishes original articles, reviews, commentaries and guidelines on tumor marker use. All submissions are subject to rigorous peer review and are selected on the basis of whether the research is sound and deserves publication. Tumor Biology is the Official Journal of the International Society of Oncology and BioMarkers (ISOBM).